Monotherapy with the Once Weekly Long-Acting GLP-1 Analog LY2189265 for 12 Weeks in Patients with Type 2 Diabetes: Dose-Dependent Effects on Glycemic Control in a Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Grunberger, George
Chang, Anna
Garcia Soria, Martin Gustavo
Botros, Fady T.
Bsharat, Rebhi
Milicevic, Zvonko
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1094-P
引用
收藏
页码：A300 / A300
页数：1
相关论文
共 50 条
  • [41] Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
    Zhu, Dalong
    Gan, Shenglian
    Liu, Yu
    Ma, Jianhua
    Dong, Xiaolin
    Song, Weihong
    Zeng, Jiao'e
    Wang, Guixia
    Zhao, Wenjuan
    Zhang, Qiu
    Li, Yukun
    Fang, Hui
    Lv, Xiaofeng
    Shi, Yongquan
    Tian, Haoming
    Ji, Linong
    Gao, Xin
    Zhang, Lihui
    Bao, Yuqian
    Lei, Minxiang
    Li, Ling
    Zeng, Longyi
    Li, Xiaoying
    Hou, Xinghua
    Zhao, Yu
    Hu, Tianxin
    Ge, Xiaoyun
    Zhao, Guiyu
    Li, Yongguo
    Zhang, Yi
    Chen, Li
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (08): : 627 - 636
  • [42] EFFECT OF SITAGLIPTIN ON POSTPRANDIAL GLUCAGON AND GLP-1 LEVELS IN PATIENTS WITH TYPE 1 DIABETES: INVESTIGATOR-INITIATED, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Garg, Satish K.
    Moser, Emily G.
    Bode, Bruce W.
    Klaff, Leslie J.
    Hiatt, William R.
    Beatson, Christie
    Snell-Bergeon, Janet K.
    ENDOCRINE PRACTICE, 2013, 19 (01) : 19 - 28
  • [43] Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
    Ferrannini, Ele
    Jimenez Ramos, Silvia
    Salsali, Afshin
    Tang, Weihua
    List, James F.
    DIABETES CARE, 2010, 33 (10) : 2217 - 2224
  • [44] Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial
    Smits, Mark M.
    Tonneijck, Lennart
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Diamant, Michaela
    van Raalte, Daniel H.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 176 (01) : 77 - 86
  • [45] Eight weeks of treatment with the long acting, human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: A double-blind placebo-controlled phase 2 study
    Balena, Raffaella
    Ratner, Robert
    Berria, Rachele
    Asnaghi, Veronica
    Grant, Rachela
    Snaith, John
    Boldrin, Mark
    Nauck, Michael
    DIABETES, 2008, 57 : A33 - A33
  • [46] The effect of the GLP-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled cross over study
    Kumarathurai, P.
    Anholm, C.
    Madsbad, S.
    Moelvig, J.
    Kristiansen, O.
    Nielsen, O. W.
    Haugaard, S. B.
    Sajadieh, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 123 - 123
  • [47] Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    ter Wee, Piet M.
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETES CARE, 2016, 39 (11) : 2042 - 2050
  • [48] The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial
    Najafipour, Mostafa
    Najafipour, Farzad
    Ostadrahimi, Alireza
    Ghavami, Maryam
    Razaghi, Zohreh
    Tutunchi, Helda
    Alamdari, Naimeh Mesri
    HEALTH PROMOTION PERSPECTIVES, 2024, 14 (04): : 380 - 387
  • [49] Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
    Takashi Kadowaki
    Masakazu Haneda
    Nobuya Inagaki
    Yasuo Terauchi
    Atsushi Taniguchi
    Kazuki Koiwai
    Henning Rattunde
    Hans J. Woerle
    Uli C. Broedl
    Advances in Therapy, 2014, 31 : 621 - 638
  • [50] Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
    Seino, Yutaka
    Sasaki, Takashi
    Fukatsu, Atsushi
    Ubukata, Michito
    Sakai, Soichi
    Samukawa, Yoshishige
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (07) : 1245 - 1255
12345